Fractyl Health (GUTS) Stock Price, News & Analysis

Company Overview

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Key Stats

• Today's Range: $1.61 to $1.68
• 50-Day Range: $1.20 to $2.88
• 52-Week Range: $0.87 to $4.92
• Volume: 149,311 shs
• Average Volume: 367,268 shs
• Market Capitalization: $80.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Buy

Fractyl Health Stock Analysis - MarketRank™

Fractyl Health scored higher than 41% of companies evaluated by MarketBeat, and ranked 1978th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Fractyl Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Fractyl Health has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Fractyl Health are expected to decrease in the coming year, from ($1.61) to ($1.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fractyl Health is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fractyl Health is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fractyl Health has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.93% of the float of Fractyl Health has been sold short.

Short Interest Ratio / Days to Cover

Fractyl Health has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Fractyl Health has recently decreased by 9.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fractyl Health does not currently pay a dividend.

Dividend Growth

Fractyl Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.93% of the float of Fractyl Health has been sold short.

Short Interest Ratio / Days to Cover

Fractyl Health has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Fractyl Health has recently decreased by 9.12%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

6 people have searched for GUTS on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Fractyl Health to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fractyl Health insiders have not sold or bought any company stock.

GUTS Stock Analysis - Frequently Asked Questions

How have GUTS shares performed this year?

Fractyl Health's stock was trading at $2.06 at the start of the year. Since then, GUTS shares have decreased by 20.6% and is now trading at $1.6350.

How were Fractyl Health's earnings last quarter?

Fractyl Health, Inc. (NASDAQ:GUTS) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.49) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.49). Fractyl Health had a negative trailing twelve-month return on equity of 228.66% and a negative net margin of 73,864.52%.
Read the conference call transcript.

When did Fractyl Health IPO?

Fractyl Health (GUTS) raised $110 million in an initial public offering (IPO) on Friday, February 2nd 2024. The company issued 7,333,333 shares at a price of $15.00 per share.

How do I buy shares of Fractyl Health?

Shares of GUTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Fractyl Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fractyl Health investors own include SoFi Technologies (SOFI), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Alphabet (GOOG), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:GUTS
• Previous Symbol: NASDAQ:GUTS
• CIK: 1572616
• Web: fractyl.com
• Phone: 781-902-8800
• Fax: N/A
• Employees: 102
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +572.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.69 million
• Net Margins: -73,864.52%
• Pretax Margin: -148,511.67%
• Return on Equity: -228.66%
• Return on Assets: -76.74%

Debt

• Debt-to-Equity Ratio: 4.61
• Current Ratio: 2.50
• Quick Ratio: 2.50

Sales & Book Value

• Annual Sales: $90 thousand
• Price / Sales: 889.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.59 per share
• Price / Book: 2.77

Miscellaneous

• Outstanding Shares: 48,980,000
• Free Float: N/A
• Market Cap: $80.08 million
• Optionable: N/A
• Beta: 1.58